Twist Bioscience Collaborates with Synthetic Design Lab
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Sep. 2, 2025– Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL).
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel’s Research Advisory Board (RAB).
Mass General Brigham Launches Genetic Test Developed in Collaboration with Broad Clinical Labs to Predict Risk Across Eight Cardiovascular Conditions
BOSTON, Sept. 3, 2025 /PRNewswire/ — In a step forward for genomic-driven preventive medicine, Mass General Brigham Personalized Medicine and the Massachusetts General Hospital’s Cardiovascular Disease Prevention Center and Center for Genomic Medicine today announced the launch of an innovative genetic test designed to estimate an individual’s inherited risk for eight chronic cardiovascular conditions. The clinician-ordered test is now available to patients on a self-pay basis.
RNAConnect® Announces Commercial Launch of UltraMarathonRT® cDNA Synthesis and Amplification Kit for Enhanced Short-Read RNA Sequencing
RNAConnect, a leader in next-generation molecular biology tools, today announced the commercial launch of the UltraMarathonRT cDNA Synthesis
Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution
CAMBRIDGE, Mass., July 23, 2025 (Everygene) — Everygene launches no-cost genetic testing for cardiomyopathy patients, partnering with Broad Clinical Labs and Mass General Brigham to enhance diagnosis using advanced genomic technology.
Everygene Launches No-Cost Genetic Testing for Cardiomyopathy with Broad Clinical Labs and Mass General Brigham
CAMBRIDGE, Mass., July 23, 2025 (Everygene) — Everygene launches no-cost genetic testing for cardiomyopathy patients, partnering with Broad Clinical Labs and Mass General Brigham to enhance diagnosis using advanced genomic technology.
Alloy Therapeutics and KSAC Announce Strategic Collaboration to Boost Japanese Biotech Startups
BOSTON, MA and TOKYO, JAPAN, July 22, 2025 (Alloy Therapeutics) — Alloy Japan and KSAC partner to boost Japanese life science startups with global biopharma support.
From Seattle to Chiba: Okayama University Taps AGC Biologics’ Global Pathway for New Therapeutic
SEATTLE, USA and CHIBA, Japan, July 17, 2025 (AGC Biologics) — Okayama University partners with AGC Biologics to develop a new therapeutic using CHEF1™ technology.
Alloy Therapeutics and Serbia’s BIO4 Campus Partner to Advance Global Bioeconomy and Biotech Innovation
Boston, MA, July 15, 2025 (Alloy Therapeutics) — Alloy Therapeutics partners with Serbia’s BIO4 Campus to advance biotech innovation and global bioeconomy.
AGC Biologics Expands Cell Therapy to Yokohama, Japan: CAR-T & Stem Cell Services
YOKOHAMA, Japan, June 25, 2025 (AGC Biologics) — AGC Biologics expands cell therapy operations to Asia at Yokohama Technical Center, enhancing global access to advanced therapies.